

PE/Cy5 anti-human CD19

Catalog # / 2415210 / 100 tests
Size: 2415205 / 25 tests

Clone: SJ25C1

Isotype: Mouse IgG1, κ

Immunogen: NALM1 + NALM16 cells


Reactivity: Human

Preparation: The antibody was purified by affinity chromatography and conjugated with PE/Cy5 under optimal conditions. The solution is free of unconjugated PE/Cy5 and unconjugated antibody.

Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA).

Workshop Number: HCDM listed

Concentration: Lot-specific



Human peripheral blood lymphocytes were stained with CD20 (clone 2H7) Brilliant Violet 421™ and CD19 (clone SJ25C1) PE/Cy5 (left) or Mouse IgG1, κ PE/Cy5 isotype control (right).


Applications:

Applications: Flow Cytometry

Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Application Notes: Clone 14G2a is an isotype switch variant from parental hybridoma 14.18 (IgG3)¹. Additional reported applications (for the relevant formats) include: inducing apoptosis and enhancing cytotoxicity of chemotherapeutic drugs in the neuroblastoma cell line ². This clone has also been published as 14.G2a.

Application References:



Human peripheral blood lymphocytes were stained with CD4 APC and CD25 (clone M-A251) Brilliant Violet 605™ (left) or Mouse IgG1, κ Brilliant Violet 605™ isotype control (right).

Description: CD19 is a 95 kD type I transmembrane glycoprotein also known as B4. It is a member of the immunoglobulin superfamily expressed on B cells (from pro-B to blastoid B cells, absent on plasma cells) and follicular dendritic cells. CD19 is involved in B cell development, activation, and differentiation. CD19 forms a complex with CD21 (CR2) and CD81 (TAPA-1), and functions as a BCR co-receptor.

- Antigen** 1. Tedder T, *et al.* 1994. *Immunol. Today* 15:437.
- References:** 2. Bradbury L, *et al.* 1993. *J. Immunol.* 151:2915.